Development and Characterization of Levodopa Loaded Pharmacosomes for Brain Targeting via Intranasal Route: Pharmacodynamic Evaluation in Rats

Kotha, Yashaswini; Kandhula, Anil Goud; Janapareddi, Krishnaveni

doi:10.5530/jyp.2020.12s.47

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study further demonstrated more pronounced yields by the chlorotoxin-tagged liposomes suggesting target-specific effects . Treatment with L-DOPA-loaded pharmacosomes was found to attenuate motor deficits and reduce oxidative stress and neuron damage in the substantia nigra region of the brain of PD rats in a significantly pronounced manner than exhibited by free L-DOPA …”

Section: Advances Made In Pd Treatment Strategies With the Assistance...mentioning

confidence: 99%

“…154 Treatment with L-DOPAloaded pharmacosomes was found to attenuate motor deficits and reduce oxidative stress and neuron damage in the substantia nigra region of the brain of PD rats in a significantly pronounced manner than exhibited by free L-DOPA. 163 Another approach to PD treatment includes the administration of dopamine; however, exogenous dopamine has a poor BBB permeability, and thus an efficient carrier strategy might prove fruitful in increasing the bioavailability of dopamine in the brain. 148 Treatment with dopamine-loaded liposomes was found to exhibit sustained release of the loaded drug, restore motor functions, and increase striatal dopamine levels in a PD rat model.…”

Section: Nanovesicle-aided Delivery Of Drugs Targeting Dopamine Deple...mentioning

confidence: 99%

See 1 more Smart Citation

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Roy

Paul²,

Bhattacharya

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Parkinson's disease (PD) is characterized by dopaminergic neurodegeneration, resulting in dopamine depletion and motor behavior deficits. Since the discovery of L-DOPA, it has been the most prescribed drug for symptomatic relief in PD, whose prolonged use, however, causes undesirable motor fluctuations like dyskinesia and dystonia. Further, therapeutics targeting the pathological hallmarks of PD including αsynuclein aggregation, oxidative stress, neuroinflammation, and autophagy impairment have also been developed, yet PD treatment is a largely unmet success. The inception of the nanovesicle-based drug delivery approach over the past few decades brings add-on advantages to the therapeutic strategies for PD treatment in which nanovesicles (basically phospholipid-containing artificial structures) are used to load and deliver drugs to the target site of the body. The present review narrates the characteristic features of nanovesicles including their blood−brain barrier permeability and ability to reach dopaminergic neurons of the brain and finally discusses the current status of this technology in the treatment of PD. From the review, it becomes evident that with the assistance of nanovesicle technology, the therapeutic efficacy of anti-PD pharmaceuticals, phyto-compounds, as well as that of nucleic acids targeting α-synuclein aggregation gained a significant increment. Furthermore, owing to the multiple drug-carrying abilities of nanovesicles, combination therapy targeting multiple pathogenic events of PD has also found success in preclinical studies and will plausibly lead to effective treatment strategies in the near future.

show abstract

Section: Advances Made In Pd Treatment Strategies With the Assistance...mentioning

confidence: 99%

Section: Nanovesicle-aided Delivery Of Drugs Targeting Dopamine Deple...mentioning

confidence: 99%

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Roy

Paul²,

Bhattacharya

et al. 2023

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Targeting anti-tumor therapy [175] Ibuprofen and Phosphatidylcholine from soy Anti-inflammatory [176] Levodopa, egg lecithin and chitosan Parkison's treatment [177] Naproxen and soy lecithin Rheumatoid arthritis treatment [178] Rosuvastatin, soy lecithin and cholesterol Hyperlipidemia treatment [179]…”

Section: Pharmacosomesmentioning

confidence: 99%

Lipid-Based Nanovesicular Drug Delivery Systems

et al. 2021

View full text Add to dashboard Cite

In designing a new drug, considering the preferred route of administration, various requirements must be fulfilled. Active molecules pharmacokinetics should be reliable with a valuable drug profile as well as well-tolerated. Over the past 20 years, nanotechnologies have provided alternative and complementary solutions to those of an exclusively pharmaceutical chemical nature since scientists and clinicians invested in the optimization of materials and methods capable of regulating effective drug delivery at the nanometer scale. Among the many drug delivery carriers, lipid nano vesicular ones successfully support clinical candidates approaching such problems as insolubility, biodegradation, and difficulty in overcoming the skin and biological barriers such as the blood–brain one. In this review, the authors discussed the structure, the biochemical composition, and the drug delivery applications of lipid nanovesicular carriers, namely, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes, phytosomes, catanionic vesicles, and extracellular vesicles.

show abstract

Nanovesicular-Mediated Intranasal Drug Therapy for Neurodegenerative Disease

Singh,

Shukla

2023

AAPS PharmSciTech

View full text Add to dashboard Cite

Development and Characterization of Levodopa Loaded Pharmacosomes for Brain Targeting via Intranasal Route: Pharmacodynamic Evaluation in Rats

Cited by 4 publications

References 21 publications

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Combating Dopaminergic Neurodegeneration in Parkinson’s Disease through Nanovesicle Technology

Lipid-Based Nanovesicular Drug Delivery Systems

Nanovesicular-Mediated Intranasal Drug Therapy for Neurodegenerative Disease

Contact Info

Product

Resources

About